20Lighter Announces Peer-Reviewed Publication of Weight Loss Program Clinical Data

By: 20Lighter, LLC
 
BOCA RATON, Fla. - Sept. 17, 2019 - PRLog -- 20Lighter, LLC, a comprehensive weight loss program focused on the reduction of visceral fat, announced today the publication of a peer-reviewed article in the Translational Journal of the American College of Sports Medicine.

The article, titled "Prescription Thyroid Replacement Does Not Affect Outcomes in an Intensive Weight Reduction Program", highlights the experience of participants prescribed thyroid replacement medication versus those without, and was authored by 20Lighter co-founders Dr. Jessica Barnes and Dr. Gerry Dembrowski.

The report represents the first large-scale study quantifying body composition changes specifically in participants on prescription thyroid medications, and is the first to demonstrate a clinically relevant improvement in not only body weight and BMI, but also tissue hydration, body fat, and visceral fat.

"We firmly believe that weight loss programs should move away from body weight and toward endpoints such as visceral fat to truly gauge the impact on participants health", said Co-founder & CMO, Dr. Gerry Dembrowski. "There is a clear need for programs addressing more than just a number on the scale. We are proud to be the only weight loss program actively showcasing clinical data that reflects clinically meaningful improvements in physiologic and metabolic endpoints including those directly linked to cardiovascular disease risk and metabolic syndrome."

About 20Lighter, LLC

20Lighter is a holistic, lifestyle transformation solution inspiring unprecedented client engagement & incorporating cutting edge, industry leading health-related and quality of life outcomes that result in a fuller, happier life experience.

Our unique doctor supervised, patent-pending weight loss program has benefited clients looking to prevent weight-related illnesses, and had major impact on those who were already dealing with weight related health issues including type 2 diabetes, hypertension, high cholesterol, gout, sleep apnea, and metabolic syndrome.

In contrast to gimmick diets and quick fixes that produce nothing but a temporary change on the scale, the 20Lighter Program has a profound effect on inflammation in the Central Nervous System and gastrointestinal tract which leads to visceral fat accumulation & metabolic disease. The 20Lighter Program is the only program to incorporate natural strategies to address dietary inflammation, the fundamental cause of weight gain, regain after weight loss and metabolic diseases associated with fat storage. At 20Lighter we are laser-focused, we do one thing and do it extremely well…  we change lives by improving health, physical and mental well-being. To learn more visit https://20lighter.com/

Media Contact
Media Contact
Jessica W. Barnes, PhD
CEO & Co-founder
***@20lighter.com
End
Source:20Lighter, LLC
Email:***@20lighter.com Email Verified
Tags:Visceral Fat
Industry:Health
Location:Boca Raton - Florida - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share